Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

You may see a FaceTime or iMessage activation error like "iMessage waiting for activation" or "iMessage activation unsuccessful." If you get a FaceTime or iMessage ...

Diseases are abnormal conditions that have a specific set of signs and symptoms. Diseases can have an external cause, such as an infection, or an internal cause, such as autoimmune diseases ...